Product Overview
[Drug Name]
Generic Name: Rivaroxaban Tablets
Trade Name: BangYueTuo Rivaroxaban Tablets 10mg*5 Tablets
Pinyin Full Code: BangYueTuo LiFaShaBanPian 10mg*5 Tablets
[Main Ingredients]
See package insert for details
[Indications/Main Functions]
1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. For the treatment of deep vein thrombosis (DVT) in adults, reducing the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For the reduction of the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack).
[Precautions]
See package insert for details
[Drug Interactions]
1. Patients with hypersensitivity to rivaroxaban or any of the excipients in the tablets. 2. Rivaroxaban tablets are contraindicated in patients with clinically significant active bleeding. 3. Patients with liver disease and coagulation abnormalities and clinically relevant bleeding risk. 4. Pregnant and lactating women.
[Specifications]
10mg*5 tablets
[Dosage and Administration]
1. The recommended dose is 10mg of rivaroxaban taken orally once daily. If wound bleeding has stopped, the first dose should be taken between 6 and 10 hours after surgery. The length of treatment depends on each patient's risk of venous thromboembolism, which is determined by the type of orthopedic surgery they undergo. 2. For patients undergoing major hip surgery, a 5-week treatment course is recommended. For patients undergoing major knee surgery, a 2-week treatment course is recommended. If a dose is missed, the patient should immediately take rivaroxaban and continue taking it once daily the following day. Rivaroxaban can be taken with or without meals.
[Adverse Reactions]
See package insert for details.
[Contraindications]
1. Patients with allergies to rivaroxaban or any of the excipients in the tablets. 2. Patients with clinically significant active bleeding should not use Bonyto Rivaroxaban tablets. 3. Patients with liver disease, coagulation abnormalities, and clinically relevant bleeding risk. 4. Pregnant and lactating women.
